161 related articles for article (PubMed ID: 27181830)
1. Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.
Roviello G; Bottini A; Generali D
Eur Urol; 2016 Aug; 70(2):e41. PubMed ID: 27181830
[No Abstract] [Full Text] [Related]
2. Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.
Fizazi K; De Porre P; Londhe A; McGowan T; Ryan CJ
Eur Urol; 2016 Aug; 70(2):e42. PubMed ID: 27209539
[No Abstract] [Full Text] [Related]
3. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
Roviello G; Generali D; Petrioli R
Eur Urol; 2017 Feb; 71(2):e55. PubMed ID: 27543166
[No Abstract] [Full Text] [Related]
4. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
van Soest RJ; de Wit R
Eur Urol; 2017 Jan; 71(1):e9-e10. PubMed ID: 27746063
[No Abstract] [Full Text] [Related]
5. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono J
Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
[No Abstract] [Full Text] [Related]
6. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono JS
Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
[No Abstract] [Full Text] [Related]
7. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Ludmir EB; McCaw ZR; Wei LJ
Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
[No Abstract] [Full Text] [Related]
8. Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021.
Hess BA
Eur Urol; 2020 Aug; 78(2):e89-e90. PubMed ID: 32291107
[No Abstract] [Full Text] [Related]
9. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
[TBL] [Abstract][Full Text] [Related]
10. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB; Drake CG; Fizazi K
Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
[TBL] [Abstract][Full Text] [Related]
12. Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Qi F; Xu Z; Zou Q
Eur Urol; 2023 Mar; 83(3):e76-e77. PubMed ID: 36604272
[No Abstract] [Full Text] [Related]
13. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Stopsack KH
Eur Urol; 2021 Mar; 79(3):e81-e82. PubMed ID: 33358233
[No Abstract] [Full Text] [Related]
14. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Conteduca V; Lolli C; De Giorgi U
Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
[No Abstract] [Full Text] [Related]
15. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
16. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Rescigno P; de Bono JS
Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
[No Abstract] [Full Text] [Related]
17. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
18. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
Rizzo A; Mollica V; Massari F
Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
[No Abstract] [Full Text] [Related]
19. Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
Lu K
Eur Urol; 2015 Sep; 68(3):e55-6. PubMed ID: 25865060
[No Abstract] [Full Text] [Related]
20. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
Wei Y; Ye D; Zhu Y
Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
